This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Kalydeco
  • /
  • A Study to Evaluate the Safety of Long-term Ivacaf...
Clinical trial

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Read time: 3 mins
Last updated:16th Aug 2017
Identifier: NCT03277196

This is a Phase 3, 2-arm, multicenter study with an open-label ivacaftor arm and an observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have an approved Ivacaftor-Responsive mutation


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 75 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
Actual Study Start Date: August 16, 2017
Estimated Primary Completion Date: June 7, 2021
Estimated Study Completion Date: June 7, 2021

Arms:
- Experimental:
Ivacaftor Arm
- No Intervention: Observational Arm

Category Value
Date last updated at source 2019-04-23
Study type(s) Interventional
Expected enrolment 75
Study start date 2017-08-16
Estimated primary completion date 2021-06-07

View full details